Leqembi, first FDA-approved Alzheimer's drug, faces EMA rejection, but shares could potentially surge soon. See why I rate ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

which is currently under FDA review. Approval for a monthly IV dose of Leqembi is also being sought. The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the approval, saying it would ...

Jeanne Lenzer and Shannon Brownlee report Donanemab (marketed in the US as Kisunla) was developed by Eli Lilly and approved by the US Food and Drug Administration (FDA) on 2 July. It is the latest in ...

A clinical trial is testing whether an existing drug could benefit patients with Alzheimer’s disease, in hopes of making ...

Donanemab, developed by pharmaceutical giant Eli Lilly, belongs to a new class of medications designed to target beta-amyloid, a protein long believed to be the culprit behind Alzheimer’s. The U.S.

No new treatments for schizophrenia have been approved in nearly three decades ... The company is currently studying the drug in Alzheimer’s-related psychosis, and next year plans to start ...

26 (UPI) --The U.S. Food and Drug Administration has approved a new drug for adults ... A new diagnosis of Alzheimer's or other dementia often spurs a person to move from their home, new research ...

The safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is called into question in an investigation published by The BMJ.

An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...